Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
- 1 October 1999
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 117 (4), 761-769
- https://doi.org/10.1016/s0016-5085(99)70332-x
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 1997
- Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.Gut, 1996
- Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's diseaseJournal of Clinical Immunology, 1996
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Frequency of glucocorticoid resistance and dependency in Crohn's disease.Gut, 1994
- Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel diseaseGastroenterology, 1994
- Cytokines (Immunoinf lammatory Hormones) and Their Natural Regulation in Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis): A ReviewDigestive Diseases, 1994
- Lymphoma in inflammatory bowel diseaseCancer, 1992
- Cancers Complicating Organ TransplantationThe New England Journal of Medicine, 1990
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990